NCLEX Review Guide: Myasthenia Gravis

Disease Process

• Myasthenia gravis is an autoimmune neuromuscular disorder characterized by antibodies that attack acetylcholine receptors at the neuromuscular junction, preventing muscle contraction and causing weakness. The autoantibodies reduce the number of available acetylcholine receptors, which impairs neuromuscular transmission and leads to the hallmark symptom of fluctuating muscle weakness that worsens with activity and improves with rest.

Risk Factors

• Myasthenia gravis affects individuals of any age but shows a bimodal distribution with peaks in the second and third decades (predominantly females) and in the sixth and seventh decades (predominantly males). Genetic predisposition, thymus abnormalities (thymoma or thymic hyperplasia), and other autoimmune disorders increase susceptibility to developing myasthenia gravis.

Primary Symptoms

• Muscle weakness that worsens with repeated use and improves with rest is the cardinal feature of myasthenia gravis. Ocular muscles are affected first in approximately 85% of patients, causing ptosis (drooping eyelids) and diplopia (double vision). As the disease progresses, facial, bulbar (swallowing, speaking), respiratory, and limb muscles may become involved, with symptoms typically worse at the end of the day.

Myasthenic Crisis

• Myasthenic crisis is a life-threatening exacerbation characterized by severe muscle weakness affecting respiratory muscles, requiring immediate ventilatory support. This medical emergency can be triggered by infection, surgery, pregnancy, certain medications (aminoglycosides, beta-blockers, magnesium), emotional stress, or inadequate treatment, and requires prompt recognition and intervention to prevent respiratory failure.

Cholinergic Crisis

• Cholinergic crisis results from excessive cholinesterase inhibitor medication (overdose), causing increased acetylcholine at cholinergic synapses. Symptoms include increased secretions (SLUDGE: Salivation, Lacrimation, Urination, Defecation, Gastrointestinal distress, Emesis), muscle weakness, fasciculations, bradycardia, and respiratory distress, which can be difficult to distinguish from myasthenic crisis.

Primary Diagnostic Tests

• Anti-acetylcholine receptor (AChR) antibody test is positive in approximately 80-90% of patients with generalized myasthenia gravis and 50% of those with ocular myasthenia. For seronegative patients, anti-muscle-specific kinase (MuSK) and anti-lipoprotein receptor-related protein 4 (LRP4) antibody tests may be performed, as these alternative antibodies can also cause myasthenia gravis.
• Edrophonium (Tensilon) test involves administering a short-acting acetylcholinesterase inhibitor that temporarily improves muscle strength in myasthenia gravis patients. This test has largely been replaced by antibody testing but may still be used in some clinical settings to differentiate myasthenic from cholinergic crisis.
• Electromyography (EMG) with repetitive nerve stimulation shows a characteristic decremental response (reduced muscle action potential) with repeated stimulation, confirming impaired neuromuscular transmission. Single-fiber EMG is even more sensitive and can detect abnormalities in neuromuscular transmission in nearly all myasthenia gravis patients.

Pharmacological Management

• Acetylcholinesterase inhibitors such as pyridostigmine (Mestinon) are first-line symptomatic treatments that increase acetylcholine availability at the neuromuscular junction by inhibiting the enzyme that breaks down acetylcholine. These medications improve muscle strength but do not alter the underlying autoimmune process, with dosing typically scheduled to provide peak effect during periods of greatest activity.
• Immunosuppressive therapy includes corticosteroids (prednisone), azathioprine, mycophenolate mofetil, cyclosporine, and tacrolimus, which target the underlying autoimmune process. Corticosteroids are often initiated at low doses and gradually increased to avoid initial worsening of symptoms, while steroid-sparing agents are added for long-term management to minimize steroid side effects.
• Biological therapies such as rituximab (targets B cells) and eculizumab (complement inhibitor) are newer treatment options for refractory cases. These targeted therapies may be particularly effective for patients with MuSK antibody-positive myasthenia gravis who often respond poorly to conventional treatments.

Surgical and Other Interventions

• Thymectomy (surgical removal of the thymus gland) is recommended for patients with thymoma and for many patients with generalized myasthenia gravis, particularly those under 60 years with AChR antibodies. Studies show that thymectomy increases the probability of remission or improvement, with benefits that may take months to years to fully manifest.
• Plasma exchange (plasmapheresis) provides rapid but temporary improvement by removing circulating antibodies from the bloodstream. This intervention is particularly useful for myasthenic crisis, preparing patients for surgery, or when rapid improvement is needed, with effects typically lasting 4-6 weeks.
• Intravenous immunoglobulin (IVIG) therapy modulates the immune response and provides rapid improvement similar to plasmapheresis. IVIG is indicated for myasthenic crisis, rapid deterioration, or preparation for surgery, with the advantage of being less invasive than plasmapheresis but carrying risks of aseptic meningitis, renal dysfunction, and thrombotic events.

Assessment

• Perform thorough neuromuscular assessment focusing on ocular (ptosis, extraocular movements), bulbar (speech, swallowing), respiratory (vital capacity, negative inspiratory force), and limb muscle strength. Assessment should be scheduled at consistent times and repeated throughout the day to detect the characteristic diurnal pattern of weakness, with special attention to respiratory parameters as declining function may indicate impending crisis.

Nursing Interventions

1. Medication Management: Administer acetylcholinesterase inhibitors on schedule to maintain therapeutic levels, particularly timing doses 30-45 minutes before meals for patients with bulbar symptoms to optimize swallowing ability.
2. Respiratory Support: Position patient upright to maximize respiratory efficiency, encourage deep breathing exercises, and have emergency equipment readily available. Monitor respiratory parameters (vital capacity, negative inspiratory force) regularly to detect early signs of respiratory compromise.
3. Nutritional Support: Schedule meals during periods of maximum strength (typically morning), provide soft or pureed diet for patients with dysphagia, and ensure adequate rest periods before and after meals to conserve energy for eating.
4. Activity Management: Plan care activities during periods of maximum strength, typically mornings, and provide scheduled rest periods throughout the day. Assist with energy conservation techniques and prioritize essential activities.
5. Crisis Management: Recognize early signs of myasthenic or cholinergic crisis, including increasing weakness, difficulty breathing, or increased secretions, and be prepared to implement emergency protocols including respiratory support and medication adjustments.

Patient Education

• Provide comprehensive education about the disease process, medication regimen, and importance of adherence to treatment plans. Teach patients to recognize and report worsening symptoms, particularly respiratory difficulties, and to maintain a symptom diary to track patterns of weakness and medication effectiveness. Educate about medication side effects, contraindicated medications, and the importance of wearing medical alert identification.

Essential Concepts

• Myasthenia gravis is an autoimmune disorder characterized by antibodies attacking acetylcholine receptors at the neuromuscular junction, resulting in fluctuating muscle weakness that worsens with activity and improves with rest.
• Ocular symptoms (ptosis, diplopia) are typically the first manifestations, followed by potential involvement of bulbar, respiratory, and limb muscles.
• Primary treatments include acetylcholinesterase inhibitors for symptomatic relief and immunosuppressive therapies to address the underlying autoimmune process.
• Myasthenic crisis is a life-threatening emergency requiring immediate respiratory support and intensive care management.
• Nursing care focuses on medication management, respiratory monitoring, energy conservation, and patient education about disease management.

Differentiation of Similar Concepts

Common Misconceptions

• Misconception: Myasthenia gravis always presents with generalized weakness. Reality: Approximately 15% of patients have purely ocular symptoms that never progress to generalized disease.
• Misconception: All patients with myasthenia gravis have detectable antibodies. Reality: About 10-20% of patients with generalized myasthenia gravis and 50% with ocular myasthenia are seronegative for AChR antibodies.
• Misconception: Thymectomy cures myasthenia gravis. Reality: While thymectomy increases the probability of remission, it is not curative for all patients, and benefits may take years to fully manifest.

NCLEX Preparation Strategies

• Focus on recognizing the hallmark symptoms of myasthenia gravis, particularly the pattern of fluctuating weakness that worsens with activity and improves with rest. Understand the differentiation between myasthenic and cholinergic crisis, as this is a common NCLEX testing point that requires critical thinking and clinical judgment.
• Master the nursing priorities for myasthenia gravis patients, especially respiratory assessment and monitoring, as respiratory compromise is the most life-threatening complication. Know medication timing principles, contraindicated medications, and crisis management protocols.

Application to Clinical Practice

Quick Check Questions

Knowledge Mastery Checklist

• I understand the pathophysiology of myasthenia gravis and the role of acetylcholine receptor antibodies
• I can identify the characteristic pattern of fluctuating muscle weakness
• I can differentiate between myasthenic crisis and cholinergic crisis
• I understand the primary diagnostic tests for myasthenia gravis
• I know the pharmacological management including acetylcholinesterase inhibitors and immunosuppressants
• I can identify medications that are contraindicated in myasthenia gravis
• I understand the role of thymectomy, plasmapheresis, and IVIG in treatment
• I know the priority nursing interventions for patients with myasthenia gravis
• I can identify early signs of respiratory compromise requiring intervention
• I understand the key patient education points for myasthenia gravis management

Common Pitfalls to Avoid

• Pitfall: Failing to recognize respiratory compromise as the most life-threatening complication of myasthenia gravis.
• Pitfall: Confusing myasthenic crisis (undertreatment) with cholinergic crisis (overtreatment), leading to inappropriate interventions.
• Pitfall: Administering contraindicated medications that can exacerbate weakness.
• Pitfall: Scheduling all activities at once without allowing for rest periods, leading to increased fatigue and weakness.
• Pitfall: Focusing solely on medication management without addressing energy conservation, safety, and psychosocial aspects of care.